Home/Pipeline/MO-858

MO-858

Solid Tumors

Phase 1/2Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Mochida Pharmaceutical

About Mochida Pharmaceutical

Mochida Pharmaceutical is a mission-driven company focused on contributing to human health through the creation of innovative pharmaceuticals. It has achieved a dominant position in the Japanese market with a diversified portfolio and a robust, fully integrated operational model. Its core strategy balances the steady cash flows from its consumer healthcare and diagnostic businesses with targeted R&D investments in novel prescription drugs, supplemented by strategic global partnerships to access new technologies and markets. With a market capitalization of $127.8 billion, it represents a cornerstone of stability and long-term value in the biopharmaceutical sector.

View full company profile

Therapeutic Areas

Oncology Immunology & Inflammation Dermatology Gastroenterology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active